The AI in Drug Discovery Market is rapidly evolving as pharmaceutical and biotechnology companies integrate artificial intelligence into research and development workflows. AI technologies can help researchers analyze large biological datasets, identify promising therapeutic targets, screen molecules, optimize lead compounds, and support clinical development. According to Market Research Future, the market was valued at approximately USD 2.81 billion in 2025 and is projected to reach USD 23.95 billion by 2035, expanding at a CAGR of 23.9%.

The AI in Drug Discovery Market is benefiting from the rising cost of traditional drug development and the growing need to improve research efficiency. Machine learning, deep learning, natural language processing, knowledge graphs, and robotic process automation are being integrated into drug discovery workflows. Pharmaceutical companies and biotechnology firms are increasingly using AI to process genomic, proteomic, clinical, and chemical information at scale. North America currently represents the leading regional market, while Asia-Pacific is expected to record rapid expansion.